Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
In the phase 2 clinical study of GRF6021 in subjects with PD and cognitive impairment, GRF6021 demonstrated positive effects on cognitive endpoints and was safe and well tolerated by study participants.
Lead Product(s): GRF6021
Therapeutic Area: Neurology Product Name: GRF6021
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Grifols International
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
Alkahest currently has four candidates in six phase-2 clinical trials covering therapeutic products for neurodegenerative, cognitive decline, neuromuscular and ophthalmic indications .
Lead Product(s): Plasma-based therapies
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Grifols International
Deal Size: $146.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 07, 2020
Details:
The company has dosed the first subject in AKST4290-205, which will assess the effects of AKST4290 on visual acuity with loading doses of anti-VEGF in treatment-naïve neovascular AMD patients.
Lead Product(s): AKST4290
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2020
Details:
The trial, AKST4290-211, is funded in part by The Michael J. Fox Foundation for Parkinson’s Research and will evaluate the effect of AKST4290 on motor function in Parkinson’s disease.
Lead Product(s): AKST4290
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2020